---

Association of Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism in breast cancer patients of Bihar: Case-control study

---

Original Article

Author Details : Tanu Verma*, Rohit Lal, Manish Kumar, Uday Kumar, S. K. Shahi

Volume : 9, Issue : 4, Year : 2022

Article Page : 301-305

https://doi.org/10.18231/j.ijcbr.2022.059

Suggest article by email

Get Permission

---

Abstract

Background: Breast cancer (BC) is the most frequent cancer in women globally and the main cause of cancer-related mortality. MTHFR C677T is a functional polymorphism in the genes encoding a one-carbon metabolism enzyme that affect folate metabolism and may be associated with breast cancer susceptibility.
Method: We have conducted a case-control study taking 100 cases of diagnosed breast cancer and 100 healthy control. PCR-RFLP technique was used to detect the genotype of C677T polymorphism in the study population.
Result: About 35% of cases had normal genotype(C677C), 49% had the genotype C677T & rest 16% had the genotype T677T for MTHFR. Among control the frequency of C677C genotype was 55% C677T was 40% & T677T was 5%. C677T & T677T MTHFR genotype were more common in case as compared to control [?2 (2, N = 200) = 11.12, p = 0.004]. T allele frequency was significantly higher in case (40%) as compared to control (5%) [?2 (1, N = 400) = 10.91, p = 0.001]. Cases with MTHFR 677TT genotype had a significantly higher risk of BC than 677CC individual [OR=1.64 (1.03 to 2.10)] and increasing T-allele was significant in BC [OR=1.07 (0.71 to 1.33)] (P for trend = 0.04).
Conclusion: C677T of MTHFR gene has a strong correlation with breast cancer in the studied population and can be used as a prognostic marker for the development of breast cancer.
 

Keywords: Methylenetetrahydrofolate reductase (MTHFR), Polymorphism, PCR­RFLP, Folate.

How to cite : Verma T, Lal R, Kumar M, Kumar U, Shahi S K, Association of Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism in breast cancer patients of Bihar: Case-control study. Int J Clin Biochem Res 2022;9(4):301-305

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.